HC Wainwright restated their buy rating on shares of Amarin Corporation PLC (NASDAQ:AMRN) in a research report report published on Wednesday morning. HC Wainwright currently has a $10.00 target price on the biopharmaceutical company’s stock.
Other equities analysts also recently issued research reports about the company. Jefferies Group LLC reissued a buy rating and set a $7.00 target price on shares of Amarin Corporation PLC in a research report on Thursday, August 3rd. BidaskClub downgraded Amarin Corporation PLC from a strong-buy rating to a buy rating in a research report on Friday, July 28th. Zacks Investment Research raised Amarin Corporation PLC from a hold rating to a buy rating and set a $4.75 target price on the stock in a research report on Tuesday, July 11th. Finally, Cantor Fitzgerald set a $5.00 target price on Amarin Corporation PLC and gave the company a buy rating in a research report on Monday, June 12th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $7.35.
Amarin Corporation PLC (NASDAQ AMRN) opened at 3.26 on Wednesday. Amarin Corporation PLC has a one year low of $2.56 and a one year high of $4.47. The stock has a 50 day moving average of $3.87 and a 200 day moving average of $3.32. The company’s market cap is $882.78 million.
Amarin Corporation PLC (NASDAQ:AMRN) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. The firm had revenue of $44.95 million for the quarter, compared to analysts’ expectations of $40.35 million. The firm’s revenue was up 37.0% on a year-over-year basis. During the same period last year, the company earned ($0.07) earnings per share. On average, analysts anticipate that Amarin Corporation PLC will post ($0.22) earnings per share for the current fiscal year.
In other news, General Counsel Joseph T. Kennedy sold 307,911 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $4.00, for a total transaction of $1,231,644.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 3.72% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its position in shares of Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares during the period. Perkins Capital Management Inc. acquired a new position in shares of Amarin Corporation PLC during the first quarter valued at approximately $110,000. JPMorgan Chase & Co. increased its position in shares of Amarin Corporation PLC by 27.1% in the first quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 7,580 shares during the period. Private Advisor Group LLC increased its position in shares of Amarin Corporation PLC by 2.1% in the first quarter. Private Advisor Group LLC now owns 50,170 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 1,032 shares during the period. Finally, Airain ltd increased its position in shares of Amarin Corporation PLC by 382.9% in the second quarter. Airain ltd now owns 87,122 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 69,081 shares during the period. 37.57% of the stock is currently owned by hedge funds and other institutional investors.
About Amarin Corporation PLC
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.
